跳至主要內容

新聞與行事曆

新聞: 截至 2026-10-13
這些標記是什麼意思

重要性是模型對已發布報導給出的 1–5 分,不是對市場的預測。

已排定事件列上的影響是公司顯著度層級(高/中由圖譜中心度與規模判定;低僅用於人工整理的次要事件),不是對波動幅度的預測。

標記為已確認的財報日期,是 Yahoo Finance 認定由公司確認的;預估表示尚未公布。未加標記的列沒有可查的出處記錄。

經濟數據發布屬於總體經濟、不歸屬任何產業,因此在任何檢視下都會保留。沒有數值的發布表示尚未公布,頁面會直說,而不是顯示為零。

涵蓋被追蹤公司的即將到來的事件;已過去的事件會歸檔,並在可得時補上結果——這些結果都經人工整理並附引用,絕不杜撰。沒有結果的歷史列會顯示「結果待定」。

閉鎖期屆滿或指數調整的列會多出一行算術——將變得可賣出的股數,或指數基金必須買進的股數,以佔流通股的比例表示——依招股說明書或指數編製方法讀出,兩個數字都在該列註明出處。它陳述的是機制,不是價格走勢。由 IPO + 180 天推算出的閉鎖期日期會一直標為預估,直到公司自己說明為止。

未來

已排定 · 今天與明天 · 行事曆更新於 2026-10-13

10月13日週二 · 今天

10月14日週三

過往

已發布 · 最新在前

8月28日週五

合作

15:41
TIME

NVIDIA's $12.9 billion Hugging Face deal

TIME reports on NVIDIA's $12.9 billion deal for Hugging Face and the open-source/open-weight model distribution strategy behind it. Hugging Face is not a company in this universe, so only NVIDIA is tagged. The only figure carried in the cited article's headline is the $12.9 billion deal value.

文章預覽

Nvidia has reportedly agreed to buy popular AI library Hugging Face for $12.9 billion. The deal is partly a hedge against an emerging threat: AI companies which consume enormous quantities of Nvidia hardware are increasingly developing chips of their own. In a future where AI becomes centralized in a small group of players with their own chips, those companies could demand lower prices from Nvidia or bypass it altogether. Hugging Face, an online hub where developers share open AI models and datasets, gives Nvidia a stake in an alternative future, where downloadable AI models allow startups and…

NVIDIA 開啟原文 ↗

產品

14:58
24/7 Wall St.

BioNTech colorectal cancer vaccine trial fails; shares fall 8%

BioNTech's colorectal cancer vaccine trial failed, and the article reports BioNTech shares fell 8% on the news. The setback lands days after the positive late-stage readout from the rival Moderna/Merck cancer-vaccine program.

大盤 開啟原文 ↗

監管

14:53
Yahoo Finance

AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease

AbbVie has applied for European Union authorisation of a subcutaneous formulation of Skyrizi in Crohn's disease.

大盤 開啟原文 ↗

產品

14:31
GlobeNewswire

CRISPR Therapeutics presents Phase 1a CTX310 data at ESC Congress 2026

CRISPR Therapeutics presented Phase 1a data for CTX310, its in vivo ANGPTL3 gene-editing candidate, at ESC Congress 2026. The company describes deep and durable ANGPTL3 editing with triglyceride and LDL lowering. Specific percentage reductions are in the release but are not restated here.

大盤 開啟原文 ↗

監管

14:26
CNBC

FDA approves Gilead daily HIV pill designed to simplify treatment

The FDA approved a once-daily HIV pill from Gilead Sciences intended to simplify treatment for some patients, per CNBC. No trial or pricing figures are reproduced here beyond what the headline states.

大盤 開啟原文 ↗

原始消息流

所有到達的消息 · 7 天